Synthesis in European heart journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
28 authors.
Dong-Yan ZhangDepartment of Cardiovascular Medicine, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, National Research Centre for Translational Medicine, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Ruijin Er Road 197, 200025 Shanghai, China.ORCID 0000-0003-0551-971X
De-Wei AnDepartment of Cardiovascular Medicine, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, National Research Centre for Translational Medicine, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Ruijin Er Road 197, 200025 Shanghai, China.ORCID 0000-0002-1395-7050
Yu-Ling YuNon-Profit Research Association Alliance for the Promotion of Preventive Medicine, Leopoldstraat 59, BE-2800 Mechelen, Belgium.ORCID 0000-0002-8255-3770
Jesus D MelgarejoInstitute of Neuroscience, Neuro and Behavioral Health Integrated Service Unit, University of Texas Rio Grande Valley, Harlingen, TX, USA.ORCID 0000-0002-1382-1153
José BoggiaCentro de Nefrología, Departamento de Fisiopatología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay.ORCID 0000-0002-1564-8534
Dries S MartensCenter for Environmental Sciences, Hasselt University, Diepenbeek, Belgium.ORCID 0000-0001-7893-3642
Kei AsayamaNon-Profit Research Association Alliance for the Promotion of Preventive Medicine, Leopoldstraat 59, BE-2800 Mechelen, Belgium.ORCID 0000-0003-3365-0547
Takayoshi OhkuboDepartment of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan.ORCID 0000-0002-3283-8196
Katarzyna Stolarz-SkrzypekThe First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Kraków, Poland.ORCID 0000-0002-7057-7302
Sofia MalyutinaInstitute of Internal and Preventive Medicine-Branch of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russian Federation.ORCID 0000-0001-6539-0466
Lars LindSection of Geriatrics, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.ORCID 0000-0003-2335-8542
Gladys E MaestreInstitute of Neuroscience, Neuro and Behavioral Health Integrated Service Unit, University of Texas Rio Grande Valley, Harlingen, TX, USA.ORCID 0000-0001-5690-8833
Ji-Guang WangDepartment of Cardiovascular Medicine, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, National Research Centre for Translational Medicine, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Ruijin Er Road 197, 200025 Shanghai, China.ORCID 0000-0001-8511-1524
Yutaka ImaiTohoku Institute for Management of Blood Pressure, Sendai, Japan.ORCID 0000-0003-3925-8837
Kalina Kawecka-JaszczThe First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Kraków, Poland.ORCID 0000-0002-8660-2867
Marek RajzerThe First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University Medical College, Kraków, Poland.ORCID 0000-0001-7074-7263
Tim S NawrotResearch Unit Environment and Health, KU Leuven Department of Public Health and Primary Care, University of Leuven, Leuven, Belgium.ORCID 0000-0002-3583-3593
Eoin O'BrienConway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.ORCID 0000-0001-5417-7977
Wen-Yi YangDepartment of Cardiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0003-1279-0866
Jan FilipovskýDepartment of Internal Medicine II, University Hospital, Charles University Medical School, Pilsen, Czechia.ORCID 0000-0002-1535-1263
Auxiliadora GracianiDepartment of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid/CIBERESP, Madrid, Spain.ORCID 0000-0002-6211-587X
José R BanegasDepartment of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid/CIBERESP, Madrid, Spain.ORCID 0000-0001-6152-9862
Yan LiDepartment of Cardiovascular Medicine, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, National Research Centre for Translational Medicine, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Ruijin Er Road 197, 200025 Shanghai, China.ORCID 0000-0002-5825-5968
Jan A StaessenDepartment of Cardiovascular Medicine, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, National Research Centre for Translational Medicine, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Ruijin Er Road 197, 200025 Shanghai, China.ORCID 0000-0002-3026-1637
International Database of Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes Investigators
Funding
Gene-Environment Interactions in Cognition in Venezuelan FamiliesR01AG036469 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CHACON, INARA, MAESTRE, GLADYS E. · 2011 to 2015
$2.7M
A longitudinal study of mid-to late-life blood pressure profiles as risk factors for Alzheimer´s disease in HispanicsR03AG054186 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAESTRE, GLADYS E., TERWILLIGER, JOSEPH DOUGLAS · 2016 to 2017
$163k
Charles University Research FundDanish Heart Foundation 01-2-9-9A-22914Education 'Leading Academics' 2022LJ022European Research Area Net for Cardiovascular Diseases JTC2017-046-PROACTEuropean Research Council 2011-294713-EPLOREEuropean Research Council 713601-uPROPHETEuropean Union HEALTH-F4-2007-201550European Union HEALTH-F7-305507European Union LSHM-CT-2006-037093FONACIT, Caracas G-97000726Fondo de Investigación Sanitaria PI19/00665Fondo de Investigación Sanitaria PI22/1164FundaConCiencia, Maracaibo LOCTIKeio University, Japan Arteriosclerosis Prevention Fund, Ministry of Health, Labor, and Welfare, Japan H29-Junkankitou-Ippan-003 and 20FA1002Lundbeck Fonden R32-A2740Ministry of Education, Culture, Sports, Science and Technology JP19H03908Ministry of Education, Culture, Sports, Science and Technology JP19K10662Ministry of Education, Culture, Sports, Science and Technology JP19K19325Ministry of Education, Culture, Sports, Science and Technology JP19K19466Ministry of Education, Culture, Sports, Science and Technology JP20K08612Ministry of Education, Culture, Sports, Science and Technology JP20K18819Ministry of Education, Culture, Sports, Science and Technology JP21H04854Ministry of Education, Culture, Sports, Science and Technology JP21K10452Ministry of Education, Culture, Sports, Science and Technology JP21K10478Ministry of Education, Culture, Sports, Science and Technology JP21K17313Ministry of Education, Culture, Sports, Science and Technology JP21K19670Ministry of Education, Culture, Sports, Science and Technology JP22H03358Ministry of Education, Culture, Sports, Science and Technology JP22K10070Ministry of Education, Culture, Sports, Science and Technology JP23H03165Ministry of Education, Culture, Sports, Science and Technology JP23K07690Ministry of Education, Culture, Sports, Science and Technology JP23K09698Ministry of Education, Culture, Sports, Science and Technology JP23K24616Ministry of Education, Culture, Sports, Science and Technology JP23K27855Ministry of Education, Culture, Sports, Science and Technology JP24K02656Ministry of Education, Culture, Sports, Science and Technology JP24K13469National Institutes of Health and National Institute of Aging 1 R03 AG054186-01National Natural Science Foundation of China 82070432National Natural Science Foundation of China 82100445National Natural Science Foundation of China 82270469Natural Science Foundation of Shanghai 22ZR1452900NIA NIH HHS R01 AG036469NIA NIH HHS R03 AG054186RAS State Target FWNR-2024-0002Research Foundation Flanders, Ministry of the Flemish Community, Brussels, Belgium G.0881.13The National Institute of Aging and the Fogarty International Center 1-R01AG036469 A1
6 · The paper itself
Abstract
BACKGROUND AND
aimsHypertension is the predominant modifiable cardiovascular risk factor. This cohort study assessed the association of risk with the percentage of time that the ambulatory blood pressure (ABP) is within the target range (PTTR) proposed by the 2024 European Society of Cardiology (ESC) guidelines for blood pressure (BP) management.
methodsIn a person-level meta-analysis of 14 230 individuals enrolled in 14 population cohorts, systolic and diastolic ABPs were combined to assess 24-h, daytime, and nighttime PTTR with thresholds for non-elevated ABP set at <115/65, <120/70, and <110/60 mmHg, respectively.
resultsMedian 24-h PTTR was 18% (interquartile range 5-33) corresponding to 4.3 h (1.2-7.9). Over 10.9 years (median), deaths (N = 3117) and cardiovascular endpoints (N = 2265) decreased across increasing 24-h PTTR quartiles from 21.3 to 16.1 and from 20.3 to 11.3 events per 1000 person-years. The standardized multivariable-adjusted hazard ratios for 24-h PTTR were 0.57 (95% confidence interval 0.46-0.71) for mortality and 0.30 (0.23-0.39) for cardiovascular endpoints. Analyses of daytime and nighttime ABP, cardiovascular mortality, coronary endpoints and stroke, and subgroups produced confirmatory results. The 2024 ESC non-elevated 24-h PTTR, compared with the 2018 ESC/European Society of Hypertension non-hypertensive 24-h PTTR, shortened the interval required to reduce relative risk for adverse outcomes from 60% to 18% (14.4-4.3 h). Office BP, compared with 24-h PTTR, misclassified most participants with regard to BP control.
conclusionsLonger time that ABP is within the 2024 ESC target range is associated with reduced adverse outcomes; PTTR derived from ABP refines risk prediction and compared with office BP avoids misclassification of individuals with regard to BP control.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.